Protein clumps in the brain have long been associated with Alzheimer’s, but other potential causes of the condition are now ...

But new data from a recent clinical trial suggests that a previously discontinued experimental drug, called gantenerumab, ...

For years, Alzheimer’s disease has been considered a brain disorder that leads to memory loss and cognitive decline. It’s a ...

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from ...

The brain's immune cells removed plaques and helped restore a healthier environment in the brains of immunized patients. For over 30 years, scientists have focused on treating Alzheimer’s disease by ...

An early Alzheimer's treatment that removes amyloid plaques from the brain many years before symptoms arise may help delay ...

For the study, the researchers gave the study participants an experimental anti-amyloid drug. They found that 22 participants ...

A clinical trial involving individuals genetically predisposed to develop early-onset Alzheimer’s disease suggests that ...

Alzheimer’s disease is characterized by a host of recognizable cognitive symptoms, but many non-cognitive symptoms like changes in sleep, anxiety and depression can be early signs of the disease.

Research shows experimental anti-amyloid drug reduced cognitive symptom risk by 50% in people with rare genetic mutations ...

The EMA has recommended refusing marketing authorization for donanemab, a monoclonal antibody against amyloid beta, in the ...

Reiswig, like many members of his family, carries a mutation in a gene called presenilin-2, which causes his brain to overproduce amyloid plaques. His relatives who carry the mutation begin ...